REFERENCES

1. Centers for Disease Control and Prevention (U.S.). MMWR. Morbidity and mortality weekly report, Vol. 66, no. 50, December 22, 2017. Available from: https://stacks.cdc.gov/view/cdc/50243 [Last accessed on 25 Nov 2022].

2. CDC. Adult obesity facts. Available from: https://www.cdc.gov/obesity/data/adult.html [Last accessed on 25 Nov 2022].

3. Wang YC, Mcpherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815-25.

4. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384:766-81.

5. Zhou B, Lu Y, Hajifathalian K, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet. 2016;387:1513-30.

6. Centers for Disease Control and Prevention(CDC). National and state diabetes trends, 2021. Available from: https://www.cdc.gov/diabetes/library/reports/reportcard/national-state-diabetes-trends.html [Last accessed on 25 Nov 2022].

7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-38.

8. Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, type 2 diabetes, and cancer risk. Front Oncol. 2020;10:615375.

9. Lonardo F, Ballouk C. Metabolism and cancer-select topics. Metab Target Organ Damage. 2022;2:8.

10. Lonardo A, Roncucci L. The “obese liver” and gastrointestinal cancer risk. Transl Gastroenterol Hepatol. 2020;5:44.

11. Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study. J Hepatol. 2019;71:1229-36.

12. Mauvais-jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565-82.

13. Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375-82.

14. Lorenzo A, Romano L, Di Renzo L, Di Lorenzo N, Cenname G, Gualtieri P. Obesity: a preventable, treatable, but relapsing disease. Nutrition. 2020;71:110615.

15. Yu SJ, Kim W, Kim D et al. Visceral obesity predicts significant fibrosis in patients with NAFLD. Medicine. 2015;94:e2159.

16. Shi YX, Chen XY, Qiu HN, et al. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity. Scand J Gastroenterol. 2021;56:312-20.

17. Marchesini G, Petroni ML, Cortez-Pinto H. Adipose tissue-associated cancer risk: is it the fat around the liver, or the fat inside the liver? J Hepatol. 2019;71:1073-5.

18. Lind L, Salihovic S, Risérus U, et al. The plasma metabolomic profile is differently associated with liver fat, visceral adipose tissue, and pancreatic fat. J Clin Endocrinol Metab. 2021;106:e118-29.

19. Rao S, Yang X, Ohshiro K, et al. β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. Sci Transl Med. 2021;13:eabk2267.

20. Tumminia A, Vinciguerra F, Parisi M, et al. Adipose tissue, obesity and adiponectin: role in endocrine cancer risk. Int J Mol Sci. 2019;20:2863.

21. Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci. 2019;20:1190.

22. Rojas E, Rodríguez-Molina D, Bolli P et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014;16:463.

23. 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of disease study 2019. Lancet. 2022;400:569-91.

24. Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022;327:2423-33.

25. Sjöström L, Narbro K, Sjöström CD, et al. Swedish obese subjects study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-52.

26. Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi'i A. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136:104754.

27. Müller MJ, Mast M, Asbeck I, Langnäse K, Grund A. Prevention of obesity-is it possible? Obes Rev. 2001;2:15-28.

28. Centers for Disease Control and Prevention(CDC). Proven strategies. Available from: https://www.cdc.gov/nccdphp/dnpao/proven-strategies.html [Last accessed on 25 Nov 2022].

29. Palacios C, Magnus M, Arrieta A, Gallardo H, Tapia R, Espinal C. Obesity in Latin America, a scoping review of public health prevention strategies and an overview of their impact on obesity prevention. Public Health Nutr. 2021;24:5142-55.

30. Caballero B. Humans agains obesity: who will win? Adv Nutr. 2019;10:S4-9.

31. Cole HM, Fiore MC. The war against tobacco: 50 years and counting. JAMA. 2014;311:131-2.

32. Yi C, Song Z, Wan M, Chen Y, Cheng X. Statins intake and risk of liver cancer: a dose-response meta analysis of prospective cohort studies. Medicine. 2017;96:e7435.

33. Jeong GH, Lee KH, Kim JY, et al. Statin and cancer mortality and survival: an umbrella systematic review and meta-analysis. J Clin Med. 2020;9:326.